Lyka Labs Limited (LYKALABS) Price & Analysis

Compare

1 Followers

LYKALABS Stock Chart & Stats

₹94.40

-₹1.55(-0.97%)

At close: Jan 08 4:00 PM EST

₹94.40

-₹1.55(-0.97%)

Day’s Range― - ―

52-Week Range₹56.60 - ₹128.60

Previous CloseN/A

Volume78.41K

Average Volume (3M)3.02K

Market Cap

₹2.17B

Enterprise Value₹2.47B

Total Cash (Recent Filing)₹18.36M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)―

Beta1.20

Next Earnings

Jun 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding35,690,000

10 Day Avg. Volume1,252

30 Day Avg. Volume3,017

Financial Highlights & Ratios

PEG Ratio-0.12

Price to Book (P/B)3.58

Price to Sales (P/S)2.64

P/FCF Ratio-26.96

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue Growth & Margin ImprovementConsistent top-line expansion with improving EBIT and EBITDA margins suggests Lyka Labs is scaling revenue while gaining operational leverage. Durable revenue growth and margin improvement support long-term cash generation, pricing power and reinvestment capacity across product lines.

Stronger Equity / Lower LeverageRising shareholders' equity and a falling debt-to-equity ratio reduce leverage and enhance solvency. Improved equity ratio gives the company greater flexibility to fund capex or weather downturns, lowering refinancing risk and supporting strategic investments over the medium term.

Robust Gross MarginsSustained robust gross profit margin indicates effective cost controls and product mix advantages. Durable gross margins create a buffer against raw-material volatility, enable competitive pricing or R&D investment, and contribute to sustainable operating profitability over time.

Bears Say

High Total LiabilitiesPersistently high total liabilities, despite leverage improvements, constrain financial flexibility. Large obligations increase interest and refinancing exposure, limiting free cash flow available for growth or dividends and elevating solvency risk if revenue or margins weaken.

Negative Free Cash FlowNegative free cash flow driven by heavy capital expenditures undermines the firm's ability to self-finance growth. Reliance on external financing raises cost and dilution risk, restricts reserve accumulation, and can limit strategic optionality over the next several quarters.

Earnings Volatility & EPS DeclineFluctuating net margins and a sharply negative EPS growth rate indicate unstable profitability and earnings quality. This variability hampers forecasting, reduces retained earnings for reinvestment, and raises execution risk in sustaining recent margin gains long-term.

Lyka Labs Limited News

Lyka Labs Says NCLT Reserves Order on Amalgamation Scheme After FEMA Compliance Filing

Lyka Labs Limited ( ($IN:LYKALABS) ) just unveiled an announcement. Lyka Labs Limited has updated exchanges on the...

12d ago

Lyka Labs Confirms SEBI Dematerialisation Compliance for December Quarter

Lyka Labs Limited ( ($IN:LYKALABS) ) has provided an update. Lyka Labs Limited has reported that its registrar...

2M ago

Lyka Labs Updates on Amalgamation Process

Lyka Labs Limited ( ($IN:LYKALABS) ) has issued an announcement. Lyka Labs Limited has provided an update on...

5M ago

Lyka Labs Promoters Declare No Share Encumbrance

Lyka Labs Limited ( ($IN:LYKALABS) ) has issued an update. Lyka Labs Limited, a company involved in the...

11M ago

LYKALABS FAQ

What was Lyka Labs Limited’s price range in the past 12 months?

Lyka Labs Limited lowest stock price was ₹56.60 and its highest was ₹128.60 in the past 12 months.

What is Lyka Labs Limited’s market cap?

Lyka Labs Limited’s market cap is ₹2.17B.

When is Lyka Labs Limited’s upcoming earnings report date?

Lyka Labs Limited’s upcoming earnings report date is Jun 02, 2026 which is in 90 days.

How were Lyka Labs Limited’s earnings last quarter?

Lyka Labs Limited released its earnings results on Jan 29, 2026. The company reported ₹0 earnings per share for the quarter, the consensus estimate of N/A by ₹0.

Is Lyka Labs Limited overvalued?

According to Wall Street analysts Lyka Labs Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Lyka Labs Limited pay dividends?

Lyka Labs Limited does not currently pay dividends.

What is Lyka Labs Limited’s EPS estimate?

Lyka Labs Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Lyka Labs Limited have?

Lyka Labs Limited has 35,690,000 shares outstanding.

What happened to Lyka Labs Limited’s price movement after its last earnings report?

Lyka Labs Limited reported an EPS of ₹0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -3.741%.

Which hedge fund is a major shareholder of Lyka Labs Limited?

Currently, no hedge funds are holding shares in IN:LYKALABS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Lyka Labs Limited

Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, muscle relaxant, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data. In addition, it provides products and services in therapeutic categories, such as intensive care, gastroenterology, anti-infective, anti-fungal, surgery care, cosmetologist, urology, wound care, and anesthesia, as well as deals in pharmaceutical products. The company offers its products in various formulations, including injections, creams, ointments, gels, and lotions. It also exports its products to Bangladesh, Combodia, Congo, Costa Rica, Peru, Romania, Russia, Sri Lanka, Sudan, Ukraine, Venezuela, and Vietnam. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India.